References

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

10.1186/s12933-022-01604-7 · 2022 · External reference

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

10.1016/s0140-6736(18)32260-8 · 2018 · External reference

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

10.1016/s0140-6736(21)02188-7 · 2021 · External reference

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

10.1056/nejmoa2107519 · 2021 · External reference

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

10.1016/s2213-8587(22)00243-1 · 2022 · External reference

Perspectives on weight control in diabetes - tirzepatide

10.1016/j.diabres.2023.110770 · 2023 · External reference

Tirzepatide reduces high-sensitivity C-reactive protein in patients with type 2 diabetes and high cardiovascular risk: a post hoc analysis of the SURPASS-4 Trial

10.1161/circ.148.suppl_1.16779 · 2023 · External reference

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

10.1038/s41591-022-01707-4 · 2022 · External reference

Unresolved reference

External reference

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

10.1016/j.ahj.2023.09.007 · 2024 · External reference

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

10.1186/s12933-022-01601-w · 2022 · External reference

Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes

10.1056/nejmoa2505928 · 2025 · External reference

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

10.1016/s0140-6736(19)31149-3 · 2019 · External reference

Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials

10.2337/dc24-1533 · 2025 · External reference

An introduction to propensity score methods for reducing the effects of confounding in observational studies

10.1080/00273171.2011.568786 · 2011 · External reference

Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach

10.1002/sim.3549 · 2009 · External reference

Marginal structural models and causal inference in epidemiology

10.1097/00001648-200009000-00011 · 2000 · External reference

Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs

10.1111/joim.12197 · 2014 · External reference

The robust inference for the Cox proportional hazards model

10.1080/01621459.1989.10478874 · 1989 · External reference

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

10.1056/nejmoa1612917 · 2017 · External reference

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1901118 · 2019 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Liraglutide and cardiovascular outcomes in type 2 diabetes

10.1056/nejmoa1603827 · 2016 · External reference

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

10.1016/s0140-6736(18)32261-x · 2018 · External reference

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

10.1056/nejmoa2108269 · 2021 · External reference

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

10.1161/circulationaha.125.074545 · 2025 · External reference